Physician profile
Robert P Wespiser
NPI 1295783819
$2,251.99
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $597 · 2020: $436 · 2021: $679 · 2022: $522 · 2023: $17.14.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $17.14.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $17.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $347.90 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $260.50 | 2019-2022 | |
| Pfizer INC. | $220.40 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $179.29 | 2019-2022 | |
| Novo Nordisk INC | $125.32 | 2019-2022 | |
| Lilly USA, LLC | $120.66 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $119.23 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $91.98 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.78 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $86.61 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $68.43 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $68.13 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $67.91 | 2019-2023 | Eliquis |
| Astellas Pharma US INC | $61.85 | 2021-2022 | |
| Amgen INC. | $57.10 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $52.32 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $43.57 | 2021 | |
| Abbott Laboratories | $37.32 | 2021-2022 | |
| Bioventus LLC | $34.50 | 2019 | |
| Scilex Pharmaceuticals INC. | $34.08 | 2019-2020 | |
| Daiichi Sankyo INC. | $25.88 | 2022 | |
| Amarin Pharma, INC. | $22.22 | 2021 | |
| Esperion Therapeutics, INC. | $20.68 | 2020 | |
| Depuy Synthes Sales INC. | $15.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Wespiser listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.